High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
P J StiffS G Fisher

Abstract

To examine the prognostic factors associated with prolonged progression-free survival (PFS) and overall survival (OS) in 100 consecutively treated women undergoing autologous stem-cell transplant for advanced ovarian cancer. From October 1989 to February 1996, we transplanted 100 patients with ovarian cancer following chemotherapy with high-dose carboplatin, mitoxantrone, and cyclophosphamide with or without cyclosporine (n = 70); melphalan and mitoxantrone with or without paclitaxel (n = 25); or other regimens (n = 5). Their median age was 48 years (range, 23 to 65), 70% had papillary serous histology, 72% had grade III tumors, 66% were platinum-resistant, and 61% had > or = 1 cm bulk. The median number of prior regimens was two (range, one to six). Univariate and multivariate analyses were performed to examine age (< v > or = mean), stage, initial bulk, histology, grade, response to initial therapy, number of prior regimens, time from diagnosis to transplant, transplant regimen, platinum sensitivity, and bulk (< v > or = 1 cm) at transplant. The median PFS and OS times for the 100 patients were 7 and 13 months. A stepwise Cox proportional hazards model identified tumor bulk (P = .0001), and cisplatin sensitivity (P = .0249) a...Continue Reading

Citations

Dec 10, 1999·Pediatric Transplantation·J E Sanders
Sep 16, 2004·Springer Seminars in Immunopathology·Yago NietoElizabeth J Shpall
Sep 14, 2004·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M S ManoM Piccart
Jan 11, 2005·Arquivos brasileiros de endocrinologia e metabologia·Leonardo S VasconcellosAndy Petroianu
May 12, 2005·Acta Cirúrgica Brasileira·Nara Macedo Botelho BritoLorena Lira Tavares dos Santos
Aug 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F Ozols
Mar 10, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Jonathan A Ledermann
Aug 23, 2002·Current Opinion in Oncology·Emery SalomRamin Mirhashemi
Apr 27, 2004·Bone Marrow Transplantation·M MagagnoliA Santoro
Feb 27, 1999·Current Opinion in Obstetrics & Gynecology·S L McAfee, M V Seiden
Oct 5, 2001·Expert Opinion on Pharmacotherapy·E L TrimbleM C Christian
Feb 28, 2006·Bone Marrow Transplantation·J-P LotzUNKNOWN Groupe d' Intensification des traitements des Tumeurs Ovariennes (ITOV Group)
Oct 18, 2012·Journal of Experimental & Clinical Cancer Research : CR·Renaud SabatierJean-Marc Extra
Mar 4, 1998·Current Opinion in Obstetrics & Gynecology·L M Chen, J S Berek
Mar 8, 2000·The Oncologist·M Markman, M A Bookman
Jun 2, 2000·Cancer Investigation·R D BaynesW P Peters
Dec 11, 2014·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·F SelleJ P Lotz
Mar 6, 2021·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Oren SmaletzEric W Hoffman
Oct 26, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M R VeldwijkS Fruehauf
Jun 10, 2008·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Rukset Attar, Erkut Attar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
D AdkinsJ DiPersio
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Anna SuredaGrupo Español de Linformas/Transplante Autólogo de Médula Osea Spanish Cooperative Group
© 2021 Meta ULC. All rights reserved